Oncolytic adenoviral vector and methods of use
US11542526B2 · kind B2 · utility
0Cited by
33References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 21, 2020 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Apr 15, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10332
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a conditionally-replicating serotype 5 adenovirus or adenoviral vector expressing a mutant E1A protein under control of a promoter that is responsive to hypoxia and inflammation and one or more immune modulators under control of a tumor-specific promoter. The adenovirus or adenoviral vector also comprises serotype 3 fiber and hexon proteins. Also provided is a method of inducing cytotoxicity in tumor cells using a composition containing the adenovirus or adenoviral vector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.